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Getting Safely In and Out of a
Transcatheter Aortic Valve
Implantation Procedure
Vascular Complications According to the
Valvular Academic Research Consortium Criteria*
Nicolo Piazza, MD,† Patrick W. Serruys, MD, PHD,‡
Ruediger Lange, MD, PHD†
Munich, Germany; and Rotterdam, the Netherlands
The occurrence of vascular complications associated with
transcatheter aortic valve implantation (TAVI) is not sur-
prising given the use of large-bore catheters and imperfect
vascular closure devices. Vascular complications have been
reported in 2% to 30% of patients undergoing TAVI. The
conflicting reports are mainly due to heterogeneous end-
point definitions (1).
See page 851
Published in January 2011, the aims of the Valvular
Academic Research Consortium (VARC) were to arrive at
a consensus: 1) on the most appropriate clinical endpoints
reflecting device and patient effectiveness and safety; and
2) to standardize the definition of endpoints for valve-
related clinical trials (2). This multidisciplinary endeavor
brought together interventional cardiologists, cardiac sur-
geons, noninvasive cardiologists, regulatory bodies, profes-
sional societies, and industry with the hope to facilitate the
reporting, communication, and evaluation of this new
catheter-based therapy. The goal of VARC was not to
establish “utopian-like” definitions but to arrive at a con-
sensual agreement based on state-of-the-art practices and
materials.
In this issue of JACC: Cardiovascular Interventions,
Hayashida et al. (3) investigated the incidence, predictors,
and impact of VARC-related vascular complications in 127
patients undergoing transfemoral implantation with the
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f this paper to disclose.Edwards Sapien (n  99) (Edwards Lifesciences, Irvine,
alifornia) or CoreValve devices (n  28) (Medtronic Inc.,
inneapolis, Minnesota). Vascular complications were ob-
erved in 27.6% of patients (major: 17.4%, minor: 10.2%).
ajor but not minor vascular events were associated with
ncreased mortality. Furthermore, an outer Sheath diameter
o Femoral Artery minimal luminal diameter Ratio (SFAR)
atio 1.05 (i.e., outer sheath diameter to femoral artery
inimal luminal diameter) identified patients at higher risk
or major vascular events and 30-day mortality.
The investigators should be acknowledged for their de-
ailed description of vascular complications according to the
ARC definitions. Having said that, we can now begin to
nderstand that most major vascular events were due to
nterventions on the femoral or iliac artery (angioplasty,
tenting, or surgery) and the need for blood transfusions 4 U.
omplications occurred with near-equal frequency in the
emoral and iliac artery, with rare involvement of the aorta.
hereas dissections were the cause of most femoral injuries,
uptures played a bigger role in the iliac artery. The VARC
efinitions provide greater transparency and a better under-
tanding of where things may go wrong. This is especially
mportant during the adoption phase of a new catheter-
ased therapy.
Recently, Gurvitch et al. (4) reported a VARC vascular
vent rate of 17.4% (10% major, 7.4% minor) in a series of
05 patients implanted with the transfemoral Edwards
apien device. In that study, the majority (84%) of major
ascular complications were attributed to blood transfusions
4 U. Despite the use of apparently similar definitions,
hese 2 series report rather disparate vascular complication
ates. In both of these studies, retrospective adjudication of
utcomes may have led to reporting bias. By contrast, the
ifferences in vascular event rates may be the result of
ndividual clinical practice patterns (e.g., patient selection,
ascular access and closure techniques, imaging modalities).
Similar to clinical endpoint reporting, it is clear that
ignificant heterogeneity exists across hospitals with respect
o “best” TAVI clinical practices. This can be appreciated in
he pre-procedural, procedural, and post-procedural man-
gement of patients. Patient selection and procedural factors
uch as operator experience, techniques, and selection of
evice systems may thus influence the occurrence of vascular
omplications. In their report, Hayashida et al. (3) do not
rovide any details about vascular access criteria (e.g.,
inimum acceptable femoral artery diameter, calcification,
nd tortuosity thresholds). Angiography, as it appears, is
heir primary screening modality for vascular access. The
uthors reported that 58 of 127 (46%) patients did not have
pre-procedural multislice computed tomography
MSCT). We believe that MSCT is superior to angiogra-
hy for evaluating the minimal luminal diameter across the
asculature, severity of calcification, and degree of tortuos-
ty. A few rhetorical questions come to mind: Did MSCT
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860play a role in vascular access evaluation in those 69 patients
with MSCT? What was the vascular complication rate in
those 58 patients without MSCT? In these latter patients,
could vascular complications have been mitigated if MSCT
were available?
The investigators identified an SFAR ratio 1.05 (i.e.,
outer sheath diameter to femoral artery minimal luminal
diameter) as a predictor of VARC major vascular compli-
cations as well as 30-day mortality. The SFAR ratio
increased to 1.10 in the absence of calcium and decreased to
1.00 in the presence of calcium. This would imply an
increase in the manufacturer’s recommended femoral artery
minimal lumen diameter that is acceptable for TAVI. These
findings would need to be confirmed by others. Whether
the same SFAR cutoff criteria would apply to MSCT is
unclear. These findings are thought-provoking and should be
considered in future recommendations for TAVI guidance.
The learning curve associated with TAVI is multifaceted,
dynamic, and difficult to describe. It may involve a change in
patient-selection criteria, operator skills, or device selection.
To evaluate the impact of a learning curve, the first one-half
of the series (n 67) was compared with the latter one-half.
It must be noted, however, that 28 of 67 (42%) patients
from the first one-half underwent surgical cut-down of the
femoral artery. Furthermore, these patients were more likely
treated with the 22- and 24-F sheaths as opposed to the 18-
and 19-F. The “learning curve” that the investigators
describe, therefore, needs to be put into context. Part of the
VARC definition for minor vascular complications includes
closure device failure requiring interventional or surgical
correction but not associated with death, blood transfusion
4 U, or irreversible end organ damage. In the present
report, the majority of minor vascular complications were
due to Prostar (Abbott Vascular, Abbott Park, Illinois)
failures (11 of 13, 85%). We humbly believe that surgical
cut-downs for transfemoral TAVI procedures are being
underutilized. In selected patients, this can be performed
rather quickly with a small 3- to 4-cm incision that provides
direct visualization and tactile feel of calcium-free areas for
puncture and that might mitigate vascular closure device
failures. Ultrasound-guided puncture is another alternative
that can help localize calcium-free areas of the femoral
artery.Providing a specific proposal for an algorithm on how to
evaluate peripheral access for patients undergoing TAVI can
be a challenging task given the lack of evidence-based
medicine in this field and various success rates using
different endpoint definitions in the midst of heterogeneous
practice patterns. Nonetheless, peripheral vessel contrast
angiography and/or MSCT scan should be obtained in
every patient before TAVI, keeping in mind that MSCT
scan provides greater information about vessel calcification,
tortuosity, and minimal luminal diameter. In cases where
femoral access is unsuitable, transsubclavian/axillary artery,
transapical, and transaortic access routes should be further
evaluated.
Vascular complications remain to be a problem with
TAVI—herein reported in nearly one-third of patients.
Improvements in patient selection, operator experience,
selected techniques, and device iterations should diminish
the risk of vascular complications in the future. Getting in
and out of a TAVI procedure is not always easy.
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